Bouzas C, Pastor R, García S, Monserrat-Mesquida M, Martínez-González MA, Salas Salvadó J, Corella D, Goday A, Martinez JA, Alonso Gómez A.M, Fernandez O, Vioque López J, Romaguera D, López Miranda J, Estruch R, Tinahones FJ, Lapetra J, Serra Majem LL, Riquelme B, Martín Sánchez V, Pintó X, Delgado Rodríguez M, Matía P, Vidal J, Cardenas-Salas JJ, Daimiel L, Ros E, Toledo E, Manzanares JM, Gonzalez-Monge I, Muñoz MÁ, Martinez-Urbistondo D, Tojal Sierra L, Muñoz Bravo C, Miralles-Gisbert S, Martin M, García Ríos A, Castro Barquero S, Fernández-García JC, Santos-Lozano JM, Basterra-Gortari FJ, Gutiérrez-Carrasquilla L, Guillem-Saiz P, Satorres A, Abete I, Sorto-Sánchez C, Díez-Espino J, Babio N, Fitó Colomer M, Tur JA
*.
Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome. Biomed Pharmacother 2023; 161: 114561.